All In Biotech

Drug Trial Radar · NCT02514213

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Phase I, Open-label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination With INO-9012 in Men With Biochemically Relapsed (PSA) Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Dec 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

62

Actual

Start

Jul 2015

Primary completion

Dec 12, 2017

Study completion Dec 12, 2017

Sponsor

Lead sponsor
Inovio PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Aug 3, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • 2mg INO-5150 and electroporation device CELLECTRA®-5PBiological

    2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P

  • 8.5mg INO-5150 and electroporation device CELLECTRA®-5PBiological

    8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P

  • 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5PBiological

    2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P

  • 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5PBiological

    8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P

  • Electroporation using CELLECTRA®-5PDevice

    Electroporation device CELLECTRA®-5P

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of INO-5150 alone or with INO-9012 delivered via IM EP ( Incidence of adverse events, Injection site reactions, Changes in safety laboratory parameters)Time frame: 72 weeks
  2. Antigen specific immune response of INO-5150 alone or with INO-9012 delivered via IM EPTime frame: 72 weeks

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Chesapeake Urology Research Associates

    Baltimore, Maryland

  • Karmanos Cancer Institute

    Detroit, Michigan

  • GU Research Network, LLC/ Urology Cancer Center

    Omaha, Nebraska

  • Weill Cornell Medical College

    New York, New York

  • University of North Carolina Lineberger Cancer Center

    Chapel Hill, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Sidney Kimmel Cancer Center - Thomas Jefferson University

    Philadelphia, Pennsylvania

  • UPMC

    Pittsburgh, Pennsylvania

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Seattle Cancer Care Alliance

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.